
Combining GLP-1 receptor agonists with aspirin in individuals with obesity, with or without type 2 diabetes, increased cardiovascular risks compared to GLP-1 RA monotherapy. Higher risks of heart failure, ischaemic heart disease, and arrhythmias were observed, alongside more frequent adverse events.
Like
Save
Share